Metabolic Control of Smoldering Neuroinflammation.

Autor:	Peruzzotti-Jametti L; Department of Clinical Neurosciences and National Institute for Health Research (NIHR) Biomedical Research Centre, University of Cambridge, Cambridge, United Kingdom., Willis CM; Department of Clinical Neurosciences and National Institute for Health Research (NIHR) Biomedical Research Centre, University of Cambridge, Cambridge, United Kingdom., Hamel R; Department of Clinical Neurosciences and National Institute for Health Research (NIHR) Biomedical Research Centre, University of Cambridge, Cambridge, United Kingdom., Krzak G; Department of Clinical Neurosciences and National Institute for Health Research (NIHR) Biomedical Research Centre, University of Cambridge, Cambridge, United Kingdom., Pluchino S; Department of Clinical Neurosciences and National Institute for Health Research (NIHR) Biomedical Research Centre, University of Cambridge, Cambridge, United Kingdom.
Jazyk:	angličtina
Zdroj:	Frontiers in immunology [Front Immunol] 2021 Jun 23; Vol. 12, pp. 705920. Date of Electronic Publication: 2021 Jun 23 (Print Publication: 2021).
DOI:	10.3389/fimmu.2021.705920
Abstrakt:	Compelling evidence exists that patients with chronic neurological conditions, which includes progressive multiple sclerosis, display pathological changes in neural metabolism and mitochondrial function. However, it is unknown if a similar degree of metabolic dysfunction occurs also in non-neural cells in the central nervous system. Specifically, it remains to be clarified (i) the full extent of metabolic changes in tissue-resident microglia and infiltrating macrophages after prolonged neuroinflammation (e.g., at the level of chronic active lesions), and (ii) whether these alterations underlie a unique pathogenic phenotype that is amenable for therapeutic targeting. Herein, we discuss how cell metabolism and mitochondrial function govern the function of chronic active microglia and macrophages brain infiltrates and identify new metabolic targets for therapeutic approaches aimed at reducing smoldering neuroinflammation. Competing Interests: SP is co-founder, CSO, and shareholder (>5%) of CITC Ltd. and iSTEM Therapeutics and co-founder and Non-Executive Director at Asitia Therapeutics; LP-J is a shareholder of CITC Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2021 Peruzzotti-Jametti, Willis, Hamel, Krzak and Pluchino.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu